Karyopharm Therapeutics Beats Q1 Estimates with $35.07M Revenue, -$1.02 EPS
Karyopharm Therapeutics reported Q1 2026 EPS of -$1.02 vs estimate of -$1.45 and revenue of $35.07 million, exceeding forecasts. It holds negative P/E of -1.03, has completed enrollment for its Phase 3 endometrial trial with topline data expected mid-2026, and will present Phase 3 SENTRY results at ASCO June 2.
1. Q1 2026 Financial Results
Karyopharm reported Q1 2026 EPS of -$1.02 versus the -$1.45 estimate and revenue of $35.07 million led by $29.20 million in U.S. XPOVIO net sales, exceeding the $31.40 million projection.
2. Negative P/E Ratio
The company’s price-to-earnings ratio stands at -1.03, reflecting a net loss over the trailing twelve months and ongoing unprofitability.
3. Clinical Pipeline Progress
Enrollment has completed in the Phase 3 endometrial cancer trial with topline data expected mid-2026, and Phase 3 SENTRY trial results will be presented at ASCO on June 2.
4. Full-Year 2026 Guidance
Management reaffirmed revenue guidance of $130 million to $150 million for full-year 2026, supported by continued XPOVIO market growth.